Rethinking the Uterine Environment
in Repeated Implantation Failure
Although assisted reproductive technologies such as IVF
and embryo transfer continue to advance,
many patients still struggle with infertility.
In cases where high-quality embryos repeatedly fail to implant,
the issue may not lie with the embryo itself.
Instead, careful evaluation of the endometrial environment is essential.
When endometrial thickness is insufficient,
successful implantation becomes difficult.
Generally, an endometrial thickness of less than 7 mm
is associated with lower implantation rates.
Some patients present with refractory thin endometrium
that does not respond adequately to conventional hormone therapy.
In such cases, PRP (Platelet-Rich Plasma) therapy
has emerged as a potential alternative approach.
The Principle of Autologous
Platelet-Rich Plasma (PRP)
PRP (Platelet-Rich Plasma) is a treatment method
that utilizes plasma enriched with platelets,
isolated from the patient’s own blood.
Platelets contain a variety of growth factors
and cytokines that promote tissue regeneration
and angiogenesis. By leveraging these biological properties,
PRP therapy aims to stimulate recovery
and functional improvement in damaged or compromised tissues.
Intrauterine PRP Infusion
Purpose:
To enhance implantation potential
through endometrial regeneration
Indications:
Patients with endometrial thickness under 7 mm
who show poor response to conventional therapy
Procedure:
①Peripheral blood collection
②Centrifugation to isolate PRP
③Direct intrauterine infusion
This procedure is typically performed during frozen embryo transfer cycles
in patients with refractory thin endometrium.
In Korea, it has been registered as a new medical technology (HTA-2021-94),
recognizing its safety and clinical utility.
Ovarian PRP Therapy:
Attempting to Improve Diminished Ovarian Function
Recently, PRP therapy has also been applied directly to the ovaries.
In this approach, PRP is injected into ovarian tissue
to improve the ovarian microenvironment.
It is considered as an adjunctive treatment in cases such as:
Premature ovarian insufficiency
Low AMH levels
Repeated oocyte retrieval failure
The goal is to enhance follicular development conditions
through the action of intra-ovarian growth factors.
In some cases, it is combined with conventional IVF protocols.
The Most Critical Factor in PRP Therapy:
Concentration Technology
The effectiveness of PRP does not simply depend on using autologous blood.
It largely depends on how effectively platelets are concentrated.
If platelet concentration is insufficient,
growth factor levels will also be limited.
Therefore, reliable separation technology and
consistent high-concentration capability are essential.
High-Concentration PRP Solution –
Ycellbiomedical
Ycellbiomedical provides a differentiated PRP separation system
designed to maximize platelet concentration and procedural convenience.
✔ High-Concentration PRP
Compared to conventional systems,
platelet separation is more precise,
enabling higher concentration rates.
This maximizes growth factor levels and
supports enhanced regenerative potential.
✔ User-Friendly Design
A bottom lever mechanism allows precise PRP positioning,
enabling easy extraction with a standard needle.
No complex additional equipment is required,
improving procedural efficiency.
✔ Globally Verified Quality
GMP Certified
ISO Certified
Approved as a Medical Device
FDA Registered
CE MDR Certified
Notably, CE MDR represents a strengthened
European medical device regulation compared to the
former CE MDD standard.
Ycellbiomedical is the first and only PRP product in Korea
to obtain CE MDR certification,
demonstrating compliance with international safety
and quality management standards.
Infertility Treatment:
A New Approach
Infertility treatment is rarely solved by a single method.
Embryo quality, uterine environment,
and ovarian function all interact in complex ways.
For patients who do not respond to conventional therapy,
autologous PRP treatment may represent an additional option.
Particularly in cases of inadequate endometrial growth or
diminished ovarian function,
consultation with experienced medical professionals
is recommended to assess suitability.
The ultimate goal of infertility treatment
is not merely performing procedures—
but creating an environment capable of supporting pregnancy.
Selecting high-concentration PRP technology
supported by rigorous quality management
can be a meaningful part of that process.
Through continuous research and technological advancement,
new possibilities in overcoming infertility continue to emerge.
#Ycellbio #HighConcentrationPRP #PlateletRichPlasma
#RegenerativeMedicine #ReproductiveMedicine
#InfertilityTreatment #EndometrialRegeneration
#OvarianRejuvenation #MedicalDevice
#PRPSystem #PRPTechnology
#PRPKit #PRP
Rethinking the Uterine Environment
in Repeated Implantation Failure
Although assisted reproductive technologies such as IVF
and embryo transfer continue to advance,
many patients still struggle with infertility.
In cases where high-quality embryos repeatedly fail to implant,
the issue may not lie with the embryo itself.
Instead, careful evaluation of the endometrial environment is essential.
When endometrial thickness is insufficient,
successful implantation becomes difficult.
Generally, an endometrial thickness of less than 7 mm
is associated with lower implantation rates.
Some patients present with refractory thin endometrium
that does not respond adequately to conventional hormone therapy.
In such cases, PRP (Platelet-Rich Plasma) therapy
has emerged as a potential alternative approach.
The Principle of Autologous
Platelet-Rich Plasma (PRP)
PRP (Platelet-Rich Plasma) is a treatment method
that utilizes plasma enriched with platelets,
isolated from the patient’s own blood.
Platelets contain a variety of growth factors
and cytokines that promote tissue regeneration
and angiogenesis. By leveraging these biological properties,
PRP therapy aims to stimulate recovery
and functional improvement in damaged or compromised tissues.
Intrauterine PRP Infusion
Purpose:
To enhance implantation potential
through endometrial regeneration
Indications:
Patients with endometrial thickness under 7 mm
who show poor response to conventional therapy
Procedure:
①Peripheral blood collection
②Centrifugation to isolate PRP
③Direct intrauterine infusion
This procedure is typically performed during frozen embryo transfer cycles
in patients with refractory thin endometrium.
In Korea, it has been registered as a new medical technology (HTA-2021-94),
recognizing its safety and clinical utility.
Ovarian PRP Therapy:
Attempting to Improve Diminished Ovarian Function
Recently, PRP therapy has also been applied directly to the ovaries.
In this approach, PRP is injected into ovarian tissue
to improve the ovarian microenvironment.
It is considered as an adjunctive treatment in cases such as:
Premature ovarian insufficiency
Low AMH levels
Repeated oocyte retrieval failure
The goal is to enhance follicular development conditions
through the action of intra-ovarian growth factors.
In some cases, it is combined with conventional IVF protocols.
The Most Critical Factor in PRP Therapy:
Concentration Technology
The effectiveness of PRP does not simply depend on using autologous blood.
It largely depends on how effectively platelets are concentrated.
If platelet concentration is insufficient,
growth factor levels will also be limited.
Therefore, reliable separation technology and
consistent high-concentration capability are essential.
High-Concentration PRP Solution –
Ycellbiomedical
Ycellbiomedical provides a differentiated PRP separation system
designed to maximize platelet concentration and procedural convenience.
✔ High-Concentration PRP
Compared to conventional systems,
platelet separation is more precise,
enabling higher concentration rates.
This maximizes growth factor levels and
supports enhanced regenerative potential.
✔ User-Friendly Design
A bottom lever mechanism allows precise PRP positioning,
enabling easy extraction with a standard needle.
No complex additional equipment is required,
improving procedural efficiency.
✔ Globally Verified Quality
GMP Certified
ISO Certified
Approved as a Medical Device
FDA Registered
CE MDR Certified
Notably, CE MDR represents a strengthened
European medical device regulation compared to the
former CE MDD standard.
Ycellbiomedical is the first and only PRP product in Korea
to obtain CE MDR certification,
demonstrating compliance with international safety
and quality management standards.
Infertility Treatment:
A New Approach
Infertility treatment is rarely solved by a single method.
Embryo quality, uterine environment,
and ovarian function all interact in complex ways.
For patients who do not respond to conventional therapy,
autologous PRP treatment may represent an additional option.
Particularly in cases of inadequate endometrial growth or
diminished ovarian function,
consultation with experienced medical professionals
is recommended to assess suitability.
The ultimate goal of infertility treatment
is not merely performing procedures—
but creating an environment capable of supporting pregnancy.
Selecting high-concentration PRP technology
supported by rigorous quality management
can be a meaningful part of that process.
Through continuous research and technological advancement,
new possibilities in overcoming infertility continue to emerge.
#Ycellbio #HighConcentrationPRP #PlateletRichPlasma
#RegenerativeMedicine #ReproductiveMedicine
#InfertilityTreatment #EndometrialRegeneration
#OvarianRejuvenation #MedicalDevice
#PRPSystem #PRPTechnology
#PRPKit #PRP